国家神经系统疾病临床医学研究中心数据管理与共享系统

Data Management And Sharing System of China National Clinical Research Center for Neurological Diseases

Association of Lp-PLA2-A and early recurrence of vascular events after TIA and minor stroke

第一作者:Jinxi Lin

通讯作者:Yongjun Wang

基本信息

  • 负责人:Jinxi Lin
  • 数据来源: CHANCE
  • 论文编号:CHANCE20150118
  • 发表时间:2015-11-01

2015-11-01

已发表文章

发表杂志:Neurology

发表类型: Original Article

影响因子(IF): 9.91

PMID: 26311748 Pubmed原文链接 全文下载

主要研究背景及目的

To determine the association of lipoprotein-associated phospholipase A2 (Lp-PLA2) measured in the acute period and the short-term risk of recurrent vascular events in patients with TIA or minor stroke.

方法

We measured Lp-PLA2 activity (Lp-PLA2-A) in a subset of 3,201 participants enrolled in the CHANCE (Clopidogrel in High-Risk Patients with Acute Non-disabling Cerebrovascular Events) trial. Participants with TIA or minor stroke were enrolled within 24 hours of symptom onset and randomized to single or dual antiplatelet therapy. In the current analysis, the primary outcome was defined as the composite of ischemic stroke, myocardial infarction, or death within 90 days.

结论

Higher levels of Lp-PLA2-A in the acute period are associated with increased short-term risk of recurrent vascular events.

主要结果

The composite endpoint occurred in 299 of 3,021 participants (9.9%). The population average Lp-PLA2-A level was 209 ± 59 nmol/min/mL (95% confidence interval [CI] 207-211). Older age, male sex, and current smoking were associated with higher Lp-PLA2-A levels. Lp-PLA2-A was significantly associated with the primary endpoint (adjusted hazard ratio 1.07, 95% CI 1.01-1.13 for every 30 nmol/min/mL increase). Similar results were seen for ischemic stroke alone. Adjustment for low-density lipoprotein cholesterol attenuated the association between Lp-PLA2-A and the primary endpoint (adjusted hazard ratio 1.04, 95% CI 0.97-1.11 for every 30 nmol/min/mL increase).